var title_f42_20_43328="Transducer position apical 2 ch";
var content_f42_20_43328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transducer position for apical two-chamber view of the left ventricle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transducer position and beam plane for imaging the heart from the apex impulse location. This view is the two-dimensional two-chamber apical view; it is similar to a right anterior oblique angiogram of the left ventricle (LV) in that the inferior wall (IW) and anterolateral walls (A-LW) are border forming.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43328=[""].join("\n");
var outline_f42_20_43328=null;
var title_f42_20_43329="Patient information: Fibromyalgia (The Basics)";
var content_f42_20_43329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15394\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/57/40862\">",
"         Tender points in fibromyalgia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/11/42161\">",
"         Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/17/24854\">",
"         Patient information: Fibromyalgia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Fibromyalgia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/fibromyalgia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H482540499\">",
"      <span class=\"h1\">",
"       What is fibromyalgia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fibromyalgia is a condition that causes people to feel pain in the muscles all over their body. People with fibromyalgia also have &ldquo;tender points,&rdquo; places on their body that hurt when they are touched. No one knows what causes fibromyalgia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540506\">",
"      <span class=\"h1\">",
"       Can fibromyalgia be cured?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people seem to get over fibromyalgia. But in most people it cannot be cured. Even so, people can learn to deal with the condition and to lead fairly normal lives. Fibromyalgia does not get worse over time, and it is not life-threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540513\">",
"      <span class=\"h1\">",
"       Does fibromyalgia cause symptoms besides muscle pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with fibromyalgia often say they feel tired all the time and that sleep does not help them feel rested. They may also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Flu-like symptoms",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Depression and anxiety",
"       </li>",
"       <li>",
"        Stomach pain",
"       </li>",
"       <li>",
"        Too many or too few bowel movements (diarrhea or constipation)",
"       </li>",
"       <li>",
"        Pain in the bladder or the need to urinate in a hurry or often",
"       </li>",
"       <li>",
"        Problems with the jaw",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540520\">",
"      <span class=\"h1\">",
"       Is there a test for fibromyalgia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. To diagnose it, doctors and nurses have to go by symptoms. First they look for other causes of the symptoms, such as arthritis or a hormone problem. They diagnose the condition if they can find no other cause, and if a person has:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Muscle pain all over their body",
"       </li>",
"       <li>",
"        Severe tenderness in at least 11 of the 18 known &ldquo;tender points&rdquo; of fibromyalgia (",
"        <a class=\"graphic graphic_figure graphicRef53200 \" href=\"mobipreview.htm?39/57/40862\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes doctors diagnose fibromyalgia without checking for the number of tender points a person has. This might happen if the person has many areas that feel painful, and is bothered a lot by symptoms that are often caused by fibromyalgia. Some of these symptoms include feeling tired when getting up in the morning and during the day, and having trouble thinking clearly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540527\">",
"      <span class=\"h1\">",
"       How is fibromyalgia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are medicines and strategies to help with the symptoms of fibromyalgia. But there is no one treatment that works for everyone. You and your healthcare team will need to work together to find the right mix of treatments for you. In general, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to relieve pain, improve sleep, or improve mood",
"       </li>",
"       <li>",
"        Physical therapy to learn exercises and stretches",
"       </li>",
"       <li>",
"        Relaxation therapy",
"       </li>",
"       <li>",
"        Working with a counselor",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To get the best treatment, many people need a team that includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A doctor",
"       </li>",
"       <li>",
"        A physical therapist",
"       </li>",
"       <li>",
"        Someone trained in mental health (such as a social worker or counselor)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540534\">",
"      <span class=\"h1\">",
"       Be open to medicines",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse may suggest that you take a medicine normally used to treat depression or seizures. If so, be open to trying it. Even if you are not depressed and do not have seizures, these medicines may help. That is because they work on the brain areas that deal with pain. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540541\">",
"      <span class=\"h1\">",
"       What can I do on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is really important that you stay active. Walking, swimming, or biking can all help ease muscle pain. If you have not been active, it might hurt a little more when you start. But being active can help improve your symptoms.",
"     </p>",
"     <p>",
"      It is also really important that you try not to be too negative about your life. Your outlook has a big effect on how you feel pain. Do your best to be positive.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482540548\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/11/42161?source=see_link\">",
"       Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"       Patient information: Fibromyalgia (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/20/43329?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15394 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43329=[""].join("\n");
var outline_f42_20_43329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540499\">",
"      What is fibromyalgia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540506\">",
"      Can fibromyalgia be cured?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540513\">",
"      Does fibromyalgia cause symptoms besides muscle pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540520\">",
"      Is there a test for fibromyalgia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540527\">",
"      How is fibromyalgia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540534\">",
"      Be open to medicines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540541\">",
"      What can I do on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482540548\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/57/40862\">",
"      Tender points in fibromyalgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/11/42161?source=related_link\">",
"      Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=related_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43330="Nodular pleural plaques CT";
var content_f42_20_43330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Nodular pleural plaques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows bilateral nodular pleural plaques with small flecks of calcium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43330=[""].join("\n");
var outline_f42_20_43330=null;
var title_f42_20_43331="Blood lymphocyte - Normal and Wiskott-Aldrich syndrome";
var content_f42_20_43331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blood lymphocyte of a normal subject (left) and WAS patient (right), analyzed by scanning electron microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note \"bold\" appearance of WAS lymphocyte.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kenney, K, Cairns, L, Remold-O'Donnell, E, et al. Morphological abnormalities in the lymphocytes of patients with the Wiskott- Aldrich syndrome. Blood 1986; 68:1329. Copyright &copy; 1986 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43331=[""].join("\n");
var outline_f42_20_43331=null;
var title_f42_20_43332="Acetaminophen and phenylephrine: Drug information";
var content_f42_20_43332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/22/43364?source=see_link\">",
"    see \"Acetaminophen and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5635727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetafen Cold&reg; [OTC];",
"     </li>",
"     <li>",
"      Contac&reg; Cold + Flu Maximum Strength Non-Drowsy [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Sinus Headache [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Sinus PE [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Nasal Relief [OTC];",
"     </li>",
"     <li>",
"      Sinus Pain &amp; Pressure [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Pressure + Pain [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Sinus Congestion &amp; Pain Daytime [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Sinex&reg; Daytime Sinus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5635731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5635754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sinus pain/pressure: Oral: General dosing guidelines, refer to specific product labeling: Acetaminophen 325 mg and phenylephrine 5 mg/caplet: Take 2 caplets every 4 hours as needed; maximum: 12 caplets/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5635753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5635755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5635759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Contac&reg; Cold + Flu Maximum Strength Non Drowsy: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Excedrin&reg; Sinus Headache: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mapap&reg; Sinus PE, Sudafed PE&reg; Pressure + Pain: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Sinus Congestion &amp; Pain Daytime: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg [Cool Burst&reg; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, liquid filled, oral",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; DayQuil&reg; Sinex&reg; Daytime Sinus: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelcap, rapid release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Sinus Congestion &amp; Pain Daytime: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cetafen Cold&reg;: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Robitussin&reg; Peak Cold Nasal Relief: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sinus Pain &amp; Pressure: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5635729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5635757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caplets and gelcaps should be swallowed whole; do not crush, chew, or dissolve.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5635732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of sinus/nasal congestion and pressure, headache, and minor aches and pains",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5635724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5635738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5635733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, phenylephrine, or any component of the formulation; with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5635734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment; acetaminophen may cause severe hepatic toxicity with acute overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; more likely to experience adverse reactions to sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; do not exceed pediatric dosing recommendations. Not for OTC use in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium: Some products may contain sodium; use with caution in sodium restricted patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever lasting &gt;3 days. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5635744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5635743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5635747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5635756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vicks DayQuil Sinex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (24): $7.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (666 Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (12): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Contac Cold+Flu Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (24): $6.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin Sinus Headache Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (50): $5.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pyrroxate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (24): $7.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Robitussin Peak Cold Nasal Rlf Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (20): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sudafed PE Sinus Headache Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (24): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Sinus Congestion/Pain Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (24): $4.78",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5635748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation. Phenylephrine causes vasoconstriction of the arterioles of the nasal mucosa.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5635750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, \"Potentiation of Oral Anticoagulant Therapy by Acetaminophen,\"",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, \"Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, \"Potentiation of Warfarin Anticoagulation by Acetaminophen,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, \"Interaction Between Paracetamol and Coumarin Anticoagulants,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, \"Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,\"",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, \"Warfarin and Acetaminophen Interaction,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, \"Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, \"The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43332/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9232 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43332=[""].join("\n");
var outline_f42_20_43332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635731\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635754\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635753\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635755\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635759\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635729\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635757\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635732\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635724\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635738\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635733\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635734\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635744\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635743\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635747\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635756\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321810\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635750\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/22/43364?source=related_link\">",
"      Acetaminophen and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43333="Leukocytoclastic vasculitis I";
var content_f42_20_43333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocytoclastic vasculitis histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leukocytoclastic vasculitis involving the dermal papillae capillaries and venules (arrow), a finding that probably reflects an Arthus type III immune complex reaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43333=[""].join("\n");
var outline_f42_20_43333=null;
var title_f42_20_43334="Minocycline: Pediatric drug information";
var content_f42_20_43334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minocycline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"    see \"Minocycline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/53/17237?source=see_link\">",
"    see \"Minocycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dynacin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg; PAC;",
"     </li>",
"     <li>",
"      Solodyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Minocycline&reg;;",
"     </li>",
"     <li>",
"      Arestin Microspheres;",
"     </li>",
"     <li>",
"      Dom-Minocycline;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Minocycline;",
"     </li>",
"     <li>",
"      Novo-Minocycline;",
"     </li>",
"     <li>",
"      PHL-Minocycline;",
"     </li>",
"     <li>",
"      PMS-Minocycline;",
"     </li>",
"     <li>",
"      ratio-Minocycline;",
"     </li>",
"     <li>",
"      Riva-Minocycline;",
"     </li>",
"     <li>",
"      Sandoz-Minocycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1025436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Tetracycline Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1025467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"      see \"Minocycline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;8 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Oral, I.V.: Initial: 4 mg/kg followed by 2 mg/kg/dose every 12 hours; maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Adolescents: Oral: 100 mg once daily, in some patients may increase to 150-200 mg/day (Goulden, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acne, inflammatory, non-nodular, moderate to severe:",
"     </b>",
"     Children &ge;12 years and Adolescents: Oral (Solodyn&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses do not confer greater efficacy and may be associated with more acute vestibular side effects: ~1 mg/kg/dose once daily for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45-49 kg: 45 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50-59 kg: 55 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     60-71 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     72-84 kg: 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     85-96 kg: 90 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     97-110 kg: 105 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     111-125 kg: 115 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     126-136 kg: 135 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cellulitis (purulent) infection due to community-acquired MRSA:",
"     </b>",
"     Oral: Initial: 4 mg/kg; maximum dose: 200 mg; maintenance: 2 mg/kg/dose every 12 hours for 5-10 days; maximum dose: 100 mg (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Oral, I.V.: Initial: 200 mg, followed by 100 mg every 12 hours; more frequent dosing intervals may be used (100-200 mg initially, followed by 50 mg 4 times daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Oral: 50-100 mg once or twice daily (see also Solodyn&reg; dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asymptomatic meningococcal carrier state:",
"     </b>",
"     Oral: 100 mg every 12 hours for 5 days;",
"     <b>",
"      Note:",
"     </b>",
"     CDC recommendations do not mention use of minocycline for eradicating nasopharyngeal carriage of meningococcus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chlamydial or",
"      <i>",
"       Ureaplasma urealyticum",
"      </i>",
"      infection, uncomplicated (urethral, endocervical, or rectal):",
"     </b>",
"     Oral, I.V.: 100 mg every 12 hours for at least 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated (males):",
"     </b>",
"     Oral, I.V.: Without urethritis or anorectal infection: Initial: 200 mg, followed by 100 mg every 12 hours for at least 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated urethritis:",
"     </b>",
"     Oral, I.V.: 100 mg every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mycobacterium marinum",
"     </i>",
"     cutaneous infection: Oral: 100 mg every 12 hours for 6-8 weeks (",
"     <b>",
"      Note:",
"     </b>",
"     Optimal dosing has not been established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nocardiosis, cutaneous (non-CNS):",
"     </b>",
"     Oral: 100-200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"     Oral, I.V.: Initial: 200 mg, followed by 100 mg every 12 hours for 10-15 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Consider decreasing dose or extending interval between doses; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute; maximum dose: 200 mg/day (minocycline serum level may need to be monitored)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, pellet filled, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg;: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg; PAC: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dynacin&reg;: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 45 mg, 90 mg, 135 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solodyn&reg;: 45 mg [DSC], 55 mg, 65 mg, 80 mg, 90 mg [DSC], 105 mg, 115 mg, 135 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection, pellet-filled capsule",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15237430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ximino&trade; extended-release capsules: FDA approved July 2012; anticipated availability currently unknown. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1025473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     I.V.: Reconstitute vial with 5 mL of SWI and further dilute in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, Ringer&rsquo;s injection, or LR to a final concentration not to exceed 0.4 mg/mL; infuse slowly; avoid rapid administration; the manufacturer&rsquo;s labeling does not provide a recommended administration rate; other tetracyclines are typically infused over 1-2 hours; the injectable route should be used only if the oral route is not feasible or adequate; prolonged intravenous therapy may be associated with thromboplebitis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral: Administer with adequate fluid to decrease the risk of esophageal irritation and ulceration.  Administer with or without food. Swallow pellet-filled capsule and extended release tablet whole; do not chew, crush, or split. Administer antacids, calcium supplements, iron supplements, magnesium-containing laxatives, and cholestyramine 2 hours before or after minocycline.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9610387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, Ringer&rsquo;s injection, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with calcium-containing solutions (except LR)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aztreonam, cisatracurium, cyclosporine, docetaxel, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, linezolid, magnesium sulfate, melphalan, oxytocin, potassium chloride, remifentanil, sargramostim, teniposide, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, hydromorphone, meperidine, morphine, pemetrexed, propofol, thiotepa.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2934600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule (including pellet-filled), tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from heat. Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet (Solodyn&reg;): Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from heat. Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) prior to reconstitution. Reconstituted solution should be further diluted immediately. Final dilution should be administered immediately; stable at room temperature for 24 hours. Incompatible with adrenocorticotropic hormone, aminophylline, amobarbital, amphotericin B, bicarbonate infusion mixtures, calcium, cefazolin, heparin, hydrocortisone, penicillin, pentobarbital, phenytoin, whole blood.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1025437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible gram-negative and gram-positive infections involving the respiratory tract, urinary tract, and skin/soft tissue; treatment of anthrax (inhalational, cutaneous, and gastrointestinal); brucellosis; asymptomatic meningococcal carrier state; rickettsial diseases (including Rocky Mountain spotted fever, typhus fever, Q fever); nongonococcal urethritis caused by",
"     <i>",
"      Ureaplasma urealyticum",
"     </i>",
"     or",
"     <i>",
"      C. trachomatis",
"     </i>",
"     , and gonorrhea; chlamydial infections (FDA approved in ages &gt;8 years and adults); inflammatory acne vulgaris (FDA approved in ages &ge;12 years); has been used to treat",
"     <i>",
"      Nocardia",
"     </i>",
"     , cutaneous (non-CNS) infections;",
"     <i>",
"      Mycobacterium marinum",
"     </i>",
"     cutaneous infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dynacin&reg; may be confused with Dyazide&reg;, DynaCirc&reg;, Dynapen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Minocin&reg; may be confused with Indocin&reg;, Lincocin&reg;, Minizide&reg;, niacin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F196945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis, pericarditis, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels, dizziness, fatigue, fever, headache, hypoesthesia, malaise, mood changes, paresthesia, pseudotumor cerebri, sedation, seizure, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, erythema nodosum, erythematous rash, exfoliative dermatitis, hyperpigmentation of nails, maculopapular rash, photosensitivity, pigmentation of the skin and mucous membranes, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid cancer, thyroid discoloration, thyroid dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, dysphagia, enamel hypoplasia, enterocolitis, esophageal ulcerations, esophagitis, glossitis, inflammatory lesions (oral/anogenital), moniliasis, nausea, oral cavity discoloration, pancreatitis, pseudomembranous colitis, stomatitis, tooth discoloration, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Balanitis, vulvovaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Autoimmune hepatitis, hepatic cholestasis, hepatic failure, hepatitis, hyperbilirubinemia, jaundice, liver enzyme increases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, bone discoloration, joint stiffness, joint swelling, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased, interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, cough, dyspnea, pneumonitis, pulmonary infiltrate (with eosinophilia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity, lupus erythematosus, lupus-like syndrome, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1025443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to minocycline, other tetracyclines, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2934484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment; consider dosage modification in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1025444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of tetracyclines during tooth development may cause permanent discoloration of the teeth (yellow-gray to brown) and enamel hypoplasia; adult-onset tooth discoloration following long-term minocycline administration has also been reported. Do not administer to children &lt;8 years of age due to permanent discoloration of teeth and retardation of skeletal development and bone growth (risk being greatest for children &lt;4 years and in those receiving high doses). Minocycline has been associated with increases in BUN secondary to antianabolic effects. Pseudotumor cerebri has been reported rarely in infants and adolescents; use with isotretinoin has been associated with cases of pseudotumor cerebri; avoid concomitant treatment with isotretinoin. CNS effects (dizziness, lightheadedness, vertigo) may occur; patients must be cautioned about performing tasks which require mental alertness. Photosensitivity reaction may occur; avoid prolonged exposure to sunlight or tanning equipment; discontinue if skin erythema occurs. Azotemia, hyperphosphatemia, and acidosis have been reported in patients with significant renal dysfunction. Prolonged use may result in superinfection including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembraneous colitis. Minocycline can cause fetal harm if used during pregnancy; avoid use during pregnancy. Severe, sometimes fatal, hepatic injury has been associated with minocycline use; discontinue therapy if liver injury is suspected. Rash, along with eosinophilia, fever, and organ failure (Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome) has been reported; discontinue treatment immediately if DRESS syndrome is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Minocycline may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1025456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administration with iron, calcium, milk, or dairy products may decrease minocycline absorption; minocycline may decrease absorption of calcium, iron, magnesium, and zinc.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Rare spontaneous reports of congenital anomalies, including limb reduction, have been reported following maternal minocycline use. Due to limited information, a causal association cannot be established. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas, 2011). Minocycline should not be used for the treatment of acne in pregnant women, or in males or females attempting to conceive a child.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2934661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CBC, serum BUN, creatinine, liver function tests. Observe for changes in bowel frequency.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1025459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1025461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed to most body fluids, bile, and tissues; poor CNS penetration; deposits in fat for extended periods; crosses placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.14-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: I.V.: 15-23 hours; Oral: 16 hours (range: 11-26 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules and pellet filled capsules: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: 3.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 5% to 12% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1025478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/53/17237?source=see_link\">",
"      see \"Minocycline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact physician if watery or bloody stools develop. May discolor nails, skin, and teeth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. May cause lightheadedness/dizziness and impair ability to perform activities requiring mental alertness or physical coordination. Women of childbearing potential should be advised to use a second form of contraceptive to avoid becoming pregnant.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Dermatology/American Academy of Dermatology Association, \"Guidelines of Care for Acne Vulgaris Management,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(4):651-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/17276540/pubmed\" id=\"17276540\" target=\"_blank\">",
"        17276540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garner SE, Eady EA, Popescu C, et al, \"Minocycline for Acne Vulgaris: Efficacy and Safety,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2003, (1):CD002086.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/12535427/pubmed\" id=\"12535427\" target=\"_blank\">",
"        12535427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goulden V, \"Guidelines for the Management of Acne Vulgaris in Adolescents,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(5):301-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/1271621/pubmed\" id=\"1271621\" target=\"_blank\">",
"        1271621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanchez AR, Rogers RS 3rd, and Sheridan PJ, \"Tetracycline and Other Tetracycline-Derivative Staining of the Teeth and Oral Cavity,\"",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 2004, 43(10):709-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/15485524/pubmed\" id=\"15485524\" target=\"_blank\">",
"        15485524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Homenuik K, Nichol K, et al, \"The Glycylcyclines: A Comparative Review With the Tetracyclines,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(1):63-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/14723559/pubmed\" id=\"14723559\" target=\"_blank\">",
"        14723559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zouboulis CC and Piquero-Martin J, \"Update and Future of Systemic Acne Treatment,\"",
"      <i>",
"       Dermatology",
"      </i>",
"      , 2003, 206(1):37-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43334/abstract-text/12566804/pubmed\" id=\"12566804\" target=\"_blank\">",
"        12566804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12915 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43334=[""].join("\n");
var outline_f42_20_43334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025436\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025467\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15237430\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025473\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9610387\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934600\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025437\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196948\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196945\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025443\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934484\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025444\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299717\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196870\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025456\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196885\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934661\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025461\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1025478\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12915|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=related_link\">",
"      Minocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/53/17237?source=related_link\">",
"      Minocycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43335="Dantrolene: Pediatric drug information";
var content_f42_20_43335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dantrolene: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"    see \"Dantrolene: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/9/2197?source=see_link\">",
"    see \"Dantrolene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dantrium&reg;;",
"     </li>",
"     <li>",
"      Revonto&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dantrium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Malignant Hyperthermia",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperthermia, Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Nonparalytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"      see \"Dantrolene: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Spasticity:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to desired effect; if no further benefit is observed at a higher dosage, decrease dose to previous lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling: Children and Adolescents &ge;5 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &lt;50 kg:  Initial: 0.5 mg/kg/dose once daily for 7 days, increase to 0.5 mg/kg/dose 3 times per day for 7 days, increase to 1 mg/kg/dose 3 times/day for 7 days, and then increase to 2 mg/kg/dose 3 times/day; some patients may require 2 mg/kg/dose 4 times/day; maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &ge;50 kg:  Initial: 25 mg once daily for 7 days, then increase to 25 mg 3 times/daily for 7 days, then increase to 50 mg 3 times/daily for 7 days, and then increase to 100 mg 3 times/daily; some patients may require 100 mg 4 times/daily; maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing: Children and Adolescents: Initial: 0.5 mg/kg/dose twice daily (maximum dose: 25 mg); titrate frequency at 4-7 days to 3-4 times daily; then increase dose by 0.5 mg/kg increments at weekly intervals to effect; maximum daily dose: 12 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     , or 400 mg/",
"     <b>",
"      day",
"     </b>",
"     , whichever is lower (Krause, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Malignant hyperthermia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Preoperative prophylaxis:",
"     <b>",
"      Note:",
"     </b>",
"     Routine use not recommended provided that there is immediate availability of parenteral dantrolene and adequate perioperative patient management (eg, avoiding known trigger agents in susceptible patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: 4-8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3-4 divided doses for 1-2 days prior to surgery with the last dose administered approximately 3-4 hours before scheduled surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 2.5 mg/kg/dose administered approximately 1.25 hours prior to surgery (infuse over 1 hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Crisis: I.V.: 2.5 mg/kg (MHAUS recommendation, available at www.mhaus.org); continuously repeat dose until symptoms subside or a cumulative dose of 10 mg/kg is reached (rarely, some patients may require up to 30 mg/kg for initial treatment).",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer's labeling suggests an initial dose of 1 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      24-hour MH Hotline (for emergencies only):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     United States: 1-800-644-9737",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Outside the U.S.: 00-1-209-417-3722",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Postcrisis follow-up:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     MHAUS protocol suggestion: 1 mg/kg every 4-6 hours (route not specified)",
"     <b>",
"      or",
"     </b>",
"     a continuous I.V. infusion of 0.25 mg/kg/hour for at least 24 hours; further doses may be indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Manufacturer&rsquo;s recommendation: Oral: 4-8 mg/kg/day in 4 divided doses for 1-3 days; I.V. dantrolene may be used to prevent or attenuate recurrence of MH signs when oral therapy is not practical; individualize dosage beginning with 1 mg/kg or more as the clinical situation dictates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Spasticity:",
"     </b>",
"     Oral: Initial: 25 mg once daily for 7 days, increase to 25 mg 3 times/day for 7 days, increase to 50 mg 3 times/day for 7 days, and then increase to 100 mg 3 times/day; some patients may require 100 mg 4 times/day; maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to desired effect; if no further benefit is observed at a higher dosage, decrease dose to previous lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Malignant hyperthermia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Preoperative prophylaxis:",
"     <b>",
"      Note:",
"     </b>",
"     Dantrolene prophylaxis is not recommended for most MH-susceptible patients, provided nontriggering anesthetics are used and an adequate supply of dantrolene is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: 4-8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3-4 divided doses for 1-2 days prior to surgery with the last dose administered approximately 3-4 hours before scheduled surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 2.5 mg/kg/dose administered approximately 1.25 hours prior to surgery (infuse over 1 hour) with additional doses as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Crisis: I.V.: 2.5 mg/kg (MHAUS recommendation, available at www.mhaus.org); continuously repeat dose until symptoms subside or a cumulative dose of 10 mg/kg is reached (rarely, some patients may require up to 30 mg/kg for initial treatment).",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer's labeling suggests an initial dose of 1 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      24-hour MH Hotline (for emergencies only):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     United States: 1-800-644-9737",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Outside the U.S.: 00-1-209-417-3722",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Postcrisis follow-up:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     MHAUS protocol suggestion: 1 mg/kg every 4-6 hours (route not specified)",
"     <b>",
"      or",
"     </b>",
"     a continuous I.V. infusion of 0.25 mg/kg/hour for at least 24 hours; further doses may be indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Manufacturer&rsquo;s recommendation: Oral: 4-8 mg/kg/day in 4 divided doses for 1-3 days; I.V. dantrolene may be used to prevent or attenuate recurrence of MH signs when oral therapy is not practical; individualize dosage beginning with 1 mg/kg or more as the clinical situation dictates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustments in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer's labeling; use of oral dantrolene in patients with active liver disease (hepatitis or cirrhosis) is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sodium: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dantrium&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dantrium&reg;: 20 mg [contains mannitol 3 g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revonto&reg;: 20 mg [contains mannitol 3 g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Contents of capsule may be mixed with juice or liquid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Reconstitute by adding 60 mL SWI  to 20 mg vial, resultant concentration 0.333 mg/mL; shake vial for ~20 seconds or until solution is clear; no further dilution required; administer crisis doses by rapid I.V. injection; preferably in large-bore I.V. or central line; for intermittent infusion (prophylaxis doses) or continuous I.V. infusion, may transfer dose to sterile plastic bag and administer over 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F10460086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, and other acidic solutions",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Avoid excessive heat &gt;40&deg;C (104&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store unreconstituted vials and reconstituted solutions at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; use reconstituted injection within 6 hours; incompatible with dextrose and sodium chloride solutions and bacteriostatic water for injection; precipitates when placed in glass containers for infusion",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (FDA approved in all ages); preoperative/postoperative prevention and attenuation of malignant hyperthermia in susceptible individuals (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of spasticity associated with upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis (FDA approved in ages &ge;5 years and adults); preoperative/postoperative prevention and attenuation of malignant hyperthermia in susceptible individuals (FDA approved in ages &ge;5 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dantrolene prophylaxis is not routinely recommended for most malignant hyperthermia susceptible patients, provided  there is immediate availability of parenteral dantrolene and adequate perioperative patient management [eg, avoiding known trigger agents (eg, anesthetics) in susceptible patients]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dantrium&reg; may be confused with danazol, Daraprim&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Revonto&reg; may be confused with Revatio&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure (altered), heart failure, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, dizziness, drowsiness, fatigue, fever, headache, insomnia, lightheadedness, malaise, mental depression, nervousness, seizure, speech disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczematoid eruption, hair growth (abnormal), pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, dysphagia, gastric irritation, gastrointestinal hemorrhage, nausea, taste change, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, difficult erection, difficult urination, nocturia, polyuria, urinary incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, aplastic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (pain, erythema, swelling), thrombophlebitis, tissue necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, muscle weakness, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, tearing (excessive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Feeling of suffocation, pleural effusion (associated with pericarditis), pulmonary edema, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, lymphocytic lymphoma, sialorrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dantrolene or any component. Additional contraindications: Oral: Active hepatic disease (eg, hepatitis and cirrhosis); spasticity that is utilized to maintain posture or balance or to maintain increased function",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Use with caution in patients with severely impaired cardiac or pulmonary function or history of liver disease. Lightheadedness and vertigo may occur with therapy; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May cause photosensitivity; discontinue if skin erythema occurs; use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral: Use of calcium channel blockers with I.V. dantrolene may increase risk for hyperkalemia and subsequent cardiac arrest. The combination of I.V. dantrolene and calcium channel blockers is not recommended. Contains 3 g mannitol/vial for isotonicity; therefore, the patient will receive 0.375 g/kg of mannitol with the initial I.V. dantrolene dose of 2.5 mg/kg; use caution if additional mannitol therapy. Dantrolene I.V. is not the only therapeutic approach for management of malignant hyperthermia; supportive measures including discontinuing trigger agents (eg, anesthetic agents); administering oxygen; utilizing cooling methods; and monitoring blood gases, urinary output, urine color, and electrolytes must also be utilized and individualized.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With oral therapy, the potential for hepatotoxicity including symptomatic hepatitis (fatal and nonfatal) exists",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid use in clinical conditions for which dantrolene is not recommended. Hepatic injury is associated with higher doses (ie, &ge;800 mg/day) of chronic therapy and sporadic short courses; incidence is lower at doses &lt;400 mg/day but may still occur. Overt hepatitis has been most frequently observed between the third and twelfth month of therapy; risk of hepatic injury appears to be greater in females, in patients &gt;35 years of age (especially elderly patients) and in those with concomitant medication therapy that is also potentially hepatotoxic. Monitor LFTs at baseline  and regularly throughout therapy, use lowest effective dose. Discontinue if no benefit is observed after a total of 45 days of therapy, abnormal LFT&rsquo;s or signs and symptoms of jaundice occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection is an alkaline solution and extremely irritating to peripheral veins; may cause severe tissue necrosis if extravasation occurs; administer in a fast moving I.V. solution into a large vein or into a central line.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F156754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Dantrolene may enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine).  Management: This interaction has only been described with intravenous dantrolene administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: Dantrolene may enhance the neuromuscular-blocking effect of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10460044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Dantrolene crosses the human placenta. Cord blood concentrations are similar to those in the maternal plasma at term. and  dantrolene can be detected in the newborn serum at delivery. Adverse events were not observed in the newborn following maternal doses of 100 mg/day administered orally prior to delivery (Shime, 1988). Uterine atony has been reported following dantrolene injection after delivery; however, this may be due in part to the mannitol contained in the I.V. preparation (Shin, 1995; Weingarten, 1987). Prophylactic use of dantrolene is not routinely recommended in pregnant women susceptible to MH prior to obstetric surgery, if use is needed, close monitoring of the mother and newborn is recommended (Krause, 2004; Norman, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spasticity: Motor performance should be monitored for therapeutic outcomes; nausea, vomiting, and liver function tests (baseline and at appropriate intervals thereafter) should be monitored for potential hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Malignant hyperthermia: Cardiac and blood pressure monitoring; during and postacute phase: Per MHAUS protocol, patient should be observed in an ICU for at least 24 hours since recrudescence may occur; monitor for arrhythmias; monitor vital signs (including core temperature), electrolytes, ABG, CK, end tidal CO",
"     <sub>",
"      2",
"     </sub>",
"     (EtCO",
"     <sub>",
"      2",
"     </sub>",
"     )/capnography, urine output, urine myoglobin",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on skeletal muscle by interfering with release of calcium ion from the sarcoplasmic reticulum; prevents or reduces the increase in myoplasmic calcium ion concentration that activates the acute catabolic processes associated with malignant hyperthermia",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 70% (Allen, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive; metabolized to active metabolite: 5-hydroxydantrolene",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates (at birth): &sim;20 hours (Shime, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-7 years: 10 hours (range: 8.1-14.8 hours) (Lerman, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 25% excreted in urine as metabolites and unchanged drug; 45% to 50% excreted in feces via bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/9/2197?source=see_link\">",
"      see \"Dantrolene: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3946546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MHAUS (www.mhaus.org) provides educational and technical information to patients and healthcare providers; contact at 607-674-7920 or email from the &ldquo;contact&rdquo; page of the website. Triggers for the development of malignant hyperthermia in susceptible individuals include: All volatile inhalation anesthetics (desflurane, sevoflurane, isoflurane, halothane, enflurane, ether, methoxyflurane, and cyclopropane) and succinylcholine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dantrolene has been used successfully to treat neuroleptic malignant syndrome associated with antipsychotic agents such as prochlorperazine, promethazine, clozapine, and risperidone and also non-neuroleptic agents such as metoclopramide, amoxapine, and lithium. The recommended dose for this indication has not been established. Published case reports have used doses ranging from 1-10 mg/kg/day in divided doses both I.V. and orally.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although dantrolene is FDA approved in all ages for malignant hyperthermia, it does not usually occur in patients &lt;12 months of age and has not been reported at &lt;4 months of age (Chamley, 2000; Larach, 2010, Silva, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F156708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral suspension may be made with dantrolene capsules, a citric acid solution, and either simple syrup or syrup BP (containing 0.15% w/v methylhydroxybenzoate). Add the contents of five 100 mg dantrolene capsules to a citric acid solution (150 mg citric acid powder in 10 mL water); mix while adding the chosen vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL. Transfer to a calibrated bottle and add quantity of vehicle sufficient to make 100 mL. Label \"shake well\" and \"refrigerate\". Simple syrup suspension is stable for 2 days refrigerated; syrup BP suspension is stable for 30 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen GC, Cattran CB, Peterson RG, et al, \"Plasma Levels of Dantrolene Following Oral Administration in Malignant Hyperthermia-Susceptible Patients,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1988, 69(6):900-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/14661655/pubmed\" id=\"14661655\" target=\"_blank\">",
"        14661655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chamley D, Pollock NA, Stowell KM, et al, \"Malignant Hyperthermia in Infancy and Identification of Novel RYR1 Mutation,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2000, 84(4):500-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/10823104/pubmed\" id=\"10823104\" target=\"_blank\">",
"        10823104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delgado MR, Hirtz D, Aisen M, et al, \"Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 74(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/20101040/pubmed\" id=\"20101040\" target=\"_blank\">",
"        20101040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fricker RM, Hoerauf KH, Drewe J, et al, \"Secretion of Dantrolene Into Breast Milk After Acute Therapy of a Suspected Malignant Hyperthermia Crisis During Cesarean Section,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1998, 89(4):1023-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/9778021/pubmed\" id=\"9778021\" target=\"_blank\">",
"        9778021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glahn KP, Ellis FR, Halsall PJ, et al, \"Recognizing and Managing a Malignant Hyperthermia Crisis: Guidelines From the European Malignant Hyperthermia Group,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2010, 105(4):417-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/20837722/pubmed\" id=\"20837722\" target=\"_blank\">",
"        20837722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krause T, Gerbershagen MU, Fiege M, et al, \"Dantrolene - A Review of Its Pharmacology, Therapeutic Use and New Developments,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2004, 59(4):364-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/15023108/pubmed\" id=\"15023108\" target=\"_blank\">",
"        15023108",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larach MG, Gronert GA, Allen GC, et al, \"Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America From 1987 to 2006,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2010, 110(2):498-507.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/20081135/pubmed\" id=\"20081135\" target=\"_blank\">",
"        20081135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lerman J, McLeod ME, and Strong HA, \"Pharmacokinetics of Intravenous Dantrolene in Children,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1989, 70(4):625-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/2929999 /pubmed\" id=\"2929999 \" target=\"_blank\">",
"        2929999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malignant Hyperthermia Association of the United States (MHAUS), \"Guidelines and 24-Hour Hotline.\" Available at file://www.mhaus.org/healthcare-professionals/#.T6rV3VI2cTY",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norman PF and Eichhorn JH,  \"Management of Anesthetic Complications and Emergencies in the Obstetric Patient,\"",
"      <i>",
"       Obstet Gynecol Clin North Am",
"      </i>",
"      , 1995, 22(1):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/7784032/pubmed\" id=\"7784032\" target=\"_blank\">",
"        7784032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Podranski T, Bouillon T, Schumacher PM, et al, \"Compartmental Pharmacokinetics of Dantrolene in Adults: Do Malignant Hyperthermia Association Dosing Guidelines Work?\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 101(6):1695-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/16301243 /pubmed\" id=\"16301243 \" target=\"_blank\">",
"        16301243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shime J, Gare D, Andrews J, et al, \"Dantrolene in Pregnancy: Lack of Adverse Effects on the Fetus and Newborn Infant,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1988, 159(4):831-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/3177531 /pubmed\" id=\"3177531 \" target=\"_blank\">",
"        3177531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shin YK, Kim YD, Collea JV, et al, \"Effect of Dantrolene Sodium on Contractility of Isolated Human Uterine Muscle,\"",
"      <i>",
"       Int J Obstet Anesth",
"      </i>",
"      , 1995, 4(4):197-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/15637010/pubmed\" id=\"15637010\" target=\"_blank\">",
"        15637010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silva RR, Munoz DM, Alpert M, et al, \"Neuroleptic Malignant Syndrome in Children and Adolescents,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(2):187-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/9951218/pubmed\" id=\"9951218\" target=\"_blank\">",
"        9951218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weingarten AE, Korsh JI, Neuman GG, et al, \"Postpartum Uterine Atony After Intravenous Dantrolene,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1987, 66(3):269-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43335/abstract-text/3826671/pubmed\" id=\"3826671\" target=\"_blank\">",
"        3826671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13203 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43335=[""].join("\n");
var outline_f42_20_43335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708692\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156723\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156724\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057659\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057651\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156704\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156689\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057662\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10460086\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057654\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057661\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156768\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156766\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057666\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057650\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057649\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156754\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156698\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156700\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10460044\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057658\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057648\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057665\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057656\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3946546\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156708\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=related_link\">",
"      Dantrolene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/9/2197?source=related_link\">",
"      Dantrolene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43336="Clomipramine: Drug information";
var content_f42_20_43336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clomipramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/14/26853?source=see_link\">",
"    see \"Clomipramine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/37/11864?source=see_link\">",
"    see \"Clomipramine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;;",
"     </li>",
"     <li>",
"      Apo-Clomipramine&reg;;",
"     </li>",
"     <li>",
"      CO Clomipramine;",
"     </li>",
"     <li>",
"      Dom-Clomipramine;",
"     </li>",
"     <li>",
"      Novo-Clomipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of OCD:",
"     </b>",
"     Oral: Initial: 25 mg/day; may gradually increase as tolerated over the first 2 weeks to 100 mg/day in divided doses; Maintenance: May further increase to recommended maximum of 250 mg/day; may give as a single daily dose at bedtime once tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of clomipramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing clomipramine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate clomipramine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving clomipramine and potential benefits outweigh potential risks, discontinue clomipramine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume clomipramine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F153300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/37/11864?source=see_link\">",
"      see \"Clomipramine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment of OCD:",
"     </b>",
"     Oral: Children &gt;10 years: Initial: 25 mg/day and gradually increase, as tolerated, to a maximum of 3 mg/kg/day or 100 mg/day (whichever is less). Maintenance: May further increase to recommended maximum of 3 mg/kg/day or 200 mg/day (whichever is less); may give as a single daily dose at bedtime once tolerated.",
"     <b>",
"      Note:",
"     </b>",
"     The safety and efficacy of clomipramine in pediatric patients &lt;10 years of age have not been established and, therefore, dosing recommendations cannot be made.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution in patients with significantly impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anafranil&reg;: 25 mg, 50 mg, 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085910.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085910.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5076622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     During titration, may divide doses and administer with meals to decrease gastrointestinal side effects. After titration, may administer total daily dose at bedtime to decrease daytime sedation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of obsessive-compulsive disorder (OCD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F153319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depression, panic attacks, chronic pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ClomiPRAMINE may be confused with chlorproMAZINE, clevidipine, clomiPHENE, desipramine, Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anafranil&reg; may be confused with alfentanil, enalapril, nafarelin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Data shown for children reflects both children and adolescents studied in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness (54%), somnolence (54%), drowsiness, headache (52%; children 28%), fatigue (39%), insomnia (25%; children 11%), malaise, nervousness (18%; children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes (21%), hot flushes (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (84%, children 63%) constipation (47%; children 22%), nausea (33%; children 9%), dyspepsia (22%; children 13%), weight gain (18%; children 2%), diarrhea (13%; children 7%), anorexia (12%; children 22%), abdominal pain (11%), appetite increased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Ejaculation failure (42%), impotence (20%), micturition disorder (14%; children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (54%), myoclonus (13%; children 2%), myalgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Abnormal vision (18%; children 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pharyngitis (14%), rhinitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (29%; children 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Flushing (8%), orthostatic hypotension (6%), palpitation (4%), tachycardia (4%; children 2%), chest pain (4%), edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety (9%), memory impairment (9%), twitching (7%), depression (5%), concentration impaired (5%), fever (4%), hypertonia (4%), abnormal dreaming (3%), agitation (3%), confusion (3%),  migraine (3%), pain (3%), psychosomatic disorder (3%), speech disorder (3%), yawning (3%), aggressiveness (children 2%), chills (2%), depersonalization (2%), emotional lability (2%), irritability (2%), panic reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (8%), pruritus (6%), purpura (3%), dermatitis (2%), acne (2%), dry skin (2%), urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (1%), breast enlargement (2%), breast pain (1%), hot flashes (5%), lactation (nonpuerperal) (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance (8%), vomiting (7%), flatulence (6%), dental caries and teeth grinding (5%), dysphagia (2%), esophagitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: UTI (2% to 6%), micturition frequency (5%), dysuria (2%), leucorrhea (2%), vaginitis (2%), urinary retention (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (9%), back pain (6%), arthralgia (3%), paresis (children 2%), weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Lacrimation abnormal (3%), mydriasis (2%), conjunctivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Otic: Tinnitus (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Sinusitis (6%), coughing (6%), bronchospasm (2%; children 7%), epistaxis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Accommodation abnormal, albuminuria, aneurysm, anticholinergic syndrome, aphasia, apraxia, arrhythmia, ataxia, atrial flutter, blepharitis, blood in stool, bradycardia, breast fibroadenosis, bronchitis, bundle branch block, cardiac arrest, cardiac failure, catalepsy, cellulitis, cerebral hemorrhage, cervical dysplasia, cheilitis, cholinergic syndrome, choreoathetosis, chromatopsia, chronic enteritis, coma, conjunctival hemorrhage, cyanosis, deafness, dehydration, delirium, delusion, diabetes mellitus, diplopia, dyskinesia, dysphonia, dystonia, EEG abnormal, encephalopathy, endometrial hyperplasia, endometriosis, epididymitis, erythematous rash, exophthalmos, extrapyramidal disorder, extrasystoles, gastric ulcer, generalized spasm, glaucoma, glycosuria, goiter, gynecomastia, hallucinations, heart block, hematuria, hemiparesis, hemoptysis, hepatitis, hostility, hyperacusis, hypercholesterolemia, hyper-/hypoesthesia, hyperglycemia, hyper-/hypokinesia, hyper-reflexia, hyper-/hypothyroidism, hyperuricemia, hyper-/hypoventilation, hypnagogic hallucination, hypokalemia, ideation, intestinal obstruction, irritable bowel syndrome, keratitis, laryngismus, leukemoid reaction, lupus erythematosus rash, lymphadenopathy, lymphoma-like disorder, maculopapular rash, manic reaction, marrow depression, myocardial infarction, myocardial ischemia, myopathy, myositis, neuralgia, neuropathy, oculogyric crisis, oculomotor nerve paralysis, oral/pharyngeal edema, ovarian cyst, paralytic ileus, paranoia, parosmia, peptic ulcer, peripheral ischemia, phobic disorder, photophobia, photosensitivity reaction, pneumonia, polyarteritis nodosa, premature ejaculation, psychosis, pyelonephritis, pyuria, rectal hemorrhage, renal calculus, renal cyst, schizophrenic reaction, scleritis, seizure, sensory disturbance, skin ulceration, strabismus, stupor, suicidal ideation, suicide, suicide attempt, thrombophlebitis, tongue ulceration, torticollis, urinary incontinence, uterine hemorrhage, uterine inflammation, vaginal hemorrhage, vasospasm, ventricular tachycardia, visual field defect, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clomipramine, other tricyclic agents, or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either clomipramine or the MAO inhibitor); initiation of clomipramine in a patient receiving linezolid or intravenous methylene blue; use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Clomipramine is FDA approved for the treatment of OCD in children &ge;10 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: May cause seizures (relationship to dose and/or duration of therapy); do not exceed maximum doses. Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage, alcoholism, or concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: Has been associated with a high incidence of male sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: May cause weight gain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Clomipramine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension. In addition, may also cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C19 (major), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: ClomiPRAMINE may enhance the adverse/toxic effect of Milnacipran. Specifically, the incidence of euphoria and postural hypotension were higher in patients changing from clomipramine to milnacipran. ClomiPRAMINE may enhance the serotonergic effect of Milnacipran. This could result in serotonin syndrome.  Management: Coadminister with caution.  Monitor more closely for euphoria, postural hypotension, serotonin toxicity/serotonin syndrome, and other adverse events when switching from clomipramine to milnacipran or if these drugs are to be used in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F153275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum concentrations/toxicity may be increased by grapefruit juice. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort and tryptophan may increase the serotonergic effect of clomipramine, thus increasing the risk of serotonin syndrome. Clomipramine may increase the serum concentration of yohimbe. Management: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava, and yohimbe.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Withdrawal symptoms (including jitteriness, tremor, and seizures) have been observed in neonates whose mothers took clomipramine up to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F153269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on information from three mother-infant pairs, following maternal use of clomipramine 75-150 mg/day, the estimated exposure to the breast-feeding infant would be 0.4% to 4% of the weight-adjusted maternal dose. Adverse events have not been reported in nursing infants (information from seven cases). Infants should be monitored for signs of adverse events; routine monitoring of infant serum concentrations is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Anafranil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $462.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $462.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $462.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ClomiPRAMINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $78.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $106.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $140.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F153256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulse rate and blood pressure prior to and during therapy; ECG/cardiac status in older adults and patients with cardiac disease; suicidal ideation (especially at the beginning of therapy, after initiation, or when doses are increased or decreased); signs/symptoms of serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F153270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Anafranil 25 (ID);",
"     </li>",
"     <li>",
"      Anafranil Retard (AT, DK, FI, NL, SE);",
"     </li>",
"     <li>",
"      Anafranil SR (MY, NZ, SG);",
"     </li>",
"     <li>",
"      Anafranil SR 75 (IL);",
"     </li>",
"     <li>",
"      Clofranil (IN);",
"     </li>",
"     <li>",
"      Clopran (TW);",
"     </li>",
"     <li>",
"      Denapranil (MY);",
"     </li>",
"     <li>",
"      Depranil (SG);",
"     </li>",
"     <li>",
"      Equinorm (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      For-You (TW);",
"     </li>",
"     <li>",
"      Gromin (KP);",
"     </li>",
"     <li>",
"      Hydiphen (DE);",
"     </li>",
"     <li>",
"      Maronil (IL);",
"     </li>",
"     <li>",
"      Placil (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clomipramine appears to affect serotonin uptake while its active metabolite, desmethylclomipramine, affects norepinephrine uptake",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to desmethylclomipramine (DMI; active); extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Clomipramine: mean 32 hours (19-37 hours); DMI: mean 69 hours (range 54-77 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bocksberger JP, Gex-Fabry M, Gauthey L, et al, &ldquo;Clomipramine Therapy in the Geriatric Hospital: Experience With Therapeutic Drug Monitoring,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1994, 16(2):113-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/8009557/pubmed\" id=\"8009557\" target=\"_blank\">",
"        8009557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cano-Munoz JL, Montejo-Iglesias ML, Yanez-Saez RM, et al, &ldquo;Possible Serotonin Syndrome Following the Combined Administration of Clomipramine and Alprazolam,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(3):122.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dale O and Hole A, &ldquo;Biphasic Time-Course of Serum Concentrations of Clomipramine and Desmethylclomipramine After a Near-Fatal Overdose,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36(4):309-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/7975135/pubmed\" id=\"7975135\" target=\"_blank\">",
"        7975135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fortinguerra F, Clavenna A, and Bonati M, \"Psychotropic Drug Use During Breastfeeding: A Review of the Evidence,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(4):547-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/19736267/pubmed\" id=\"19736267\" target=\"_blank\">",
"        19736267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hernandez AF, Montero MN, Pla A, et al, &ldquo;Fatal Moclobemide Overdose or Death Caused by Serotonin Syndrome?&rdquo;",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1995, 40(1):128-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/7876795/pubmed\" id=\"7876795\" target=\"_blank\">",
"        7876795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuisma MJ, &ldquo;Fatal Serotonin Syndrome With Trismus,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 26(1):108.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lancelin F, Kraoul L, Flatischler N, et al, &ldquo;False-Positive Results in the Detection of Methadone in Urines of Patients Treated With Psychotropic Substances,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 2005, 51(11):2176-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/16244295/pubmed\" id=\"16244295\" target=\"_blank\">",
"        16244295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larrey D, Rueff B, Pessayre D, et al, &ldquo;Cross Hepatotoxicity Between Tricyclic Antidepressants,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1986, 27(6):726-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/3721296/pubmed\" id=\"3721296\" target=\"_blank\">",
"        3721296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ljungren B and Bojs G, &ldquo;A Case of Photosensitivity and Contact Allergy to Systemic Tricyclic Drugs, With Unusual Features,&rdquo;",
"      <i>",
"       Contact Dermatitis",
"      </i>",
"      , 1991, 24(4):259-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/1831106/pubmed\" id=\"1831106\" target=\"_blank\">",
"        1831106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberge RJ, Martin TG, Hodgman M, et al, &ldquo;Acute Chemical Pancreatitis Associated With a Tricyclic Antidepressant (Clomipramine) Overdose,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1994, 32(4):425-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/8057402/pubmed\" id=\"8057402\" target=\"_blank\">",
"        8057402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schimmell MS, Katz E, Shaag Y, et al, &ldquo;Toxic Neonatal Effects Following Maternal Clomipramine Therapy,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1991, 29(4):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/1749054/pubmed\" id=\"1749054\" target=\"_blank\">",
"        1749054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternbach H, &ldquo;Fluoxetine-Clomipramine Interaction,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(4):171-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin&reg; in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson-Biearman B, Goetz CM, Dean BS, et al, &ldquo;Anafranil&reg; Overdose: A Fatal Outcome,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1989, 31:378.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tueth MJ, &ldquo;The Serotonin Syndrome in the Emergency Department,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(8):1369.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/20/43336/abstract-text/8333648/pubmed\" id=\"8333648\" target=\"_blank\">",
"        8333648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9283 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43336=[""].join("\n");
var outline_f42_20_43336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708676\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153279\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153280\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153323\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153284\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153300\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153285\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795869\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795870\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153259\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153244\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874420\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5076622\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153262\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153319\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153332\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153321\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153265\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153248\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153317\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153253\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153275\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153254\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153268\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153288\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153269\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153267\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153256\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153270\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153247\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153264\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9283|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/14/26853?source=related_link\">",
"      Clomipramine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/37/11864?source=related_link\">",
"      Clomipramine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43337="Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer";
var content_f42_20_43337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Carl D Malchoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/20/43337/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/20/43337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thyroid tumor develops when the growth of a single thyroid epithelial cell escapes from the normal mechanisms regulating cell division and gains a selective growth advantage. Continued growth leads in time to a clinically evident tumor mass. Unregulated cell division can result from mutations in both oncogenes and tumor suppressor genes.",
"   </p>",
"   <p>",
"    Although thyroid epithelial tumors arise from the same cell type, they have diverse clinical characteristics. Most produce less thyroid hormone than normal thyroid tissue, but a few produce more. Most are adenomas, but some are slow-growing cancers and a few are highly aggressive cancers.",
"   </p>",
"   <p>",
"    An understanding of the mutations of the proto-oncogenes and tumor suppressor genes that occur in these tumors should eventually explain the diverse clinical characteristics of thyroid tumors, provide diagnostic information, and direct therapy. Some insights have already emerged; some abnormalities in tumor genes are consistently associated with specific clinical and pathologic findings. These genetic abnormalities usually represent somatic (acquired) mutations, as opposed to inherited (germline) mutations, because most thyroid tumors are sporadic and not familial. This is different from the multiple endocrine neoplasia syndromes in which the primary tumorigenic gene mutations are inherited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the tumorigenic gene changes found in thyroid epithelial (nonmedullary) tumors. A summary of these changes is found in the table (",
"    <a class=\"graphic graphic_table graphicRef68157 \" href=\"mobipreview.htm?7/54/8044\">",
"     table 1",
"    </a>",
"    ). Medullary thyroid cancer is included in this table for comparison, but is discussed elsewhere, as are the characteristics and treatment of the specific tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9560?source=see_link\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38263?source=see_link\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8440?source=see_link\">",
"     \"Overview of papillary thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21688?source=see_link\">",
"     \"Overview of follicular thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=see_link\">",
"     \"Anaplastic thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTONOMOUSLY FUNCTIONING THYROID ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomously-functioning thyroid adenomas (or nodules) are benign tumors that produce thyroid hormone. Clinically they present as a single nodule that is hyperfunctioning (\"hot\") on thyroid radionuclide scan, sometimes causing hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these tumors are caused by somatic mutations in genes that code for two proteins of the thyrotropin (TSH) stimulation cascade (",
"    <a class=\"graphic graphic_figure graphicRef81677 \" href=\"mobipreview.htm?17/54/18286\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The TSH receptor",
"     </li>",
"     <li>",
"      The alpha subunit of the guanyl nucleotide stimulatory protein (Gs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normally, TSH stimulates thyroid epithelial cells by binding to receptors on the plasma membrane of the cells. The signal is transduced by complexes formed between the alpha subunit of Gs and GTP in response to TSH-receptor binding. This results sequentially in stimulation of adenylyl cyclase activity, increased cyclic AMP production, and activation of protein kinases that stimulate thyroid cell division and hormone production. Adenylyl cyclase activity decreases when the GTP is hydrolyzed by the intrinsic GTPase activity of Gs-alpha. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19988?source=see_link\">",
"     \"Chapter 6A: Mechanisms of hormone action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Activating mutations of the TSH receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating mutations of the TSH receptor produce constitutive activation of adenylyl cyclase in the absence of TSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The thyroid follicular cell with this TSH receptor mutation divides and produces thyroid hormone without TSH stimulation, eventually becoming clinically recognized as a hot nodule. Although TSH (via the TSH receptor) also stimulates the inositol triphosphate pathway, most activating mutations of the TSH receptor do not stimulate signaling through this pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with an autonomously functioning thyroid adenoma, the frequency of TSH-receptor mutations in the adenoma varies from about 5 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. The large differences in frequency may be related to the sensitivity of the methods used to screen for the mutations or interpatient differences. Since the mutations are scattered throughout the receptor, studies of the entire receptor are most likely to identify a mutation. (In rare families, germline mutations in the TSH receptor cause hereditary hyperthyroidism, initially with a diffuse goiter but ultimately with a nodular goiter with multiple hot nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/8\">",
"     8",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gs-alpha gene mutations that activate adenylyl cyclase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gs-alpha mutations that lead to adenylyl cyclase activation have the same effects on cell division and thyroid hormone production as those in the TSH receptor (",
"    <a class=\"graphic graphic_figure graphicRef81677 \" href=\"mobipreview.htm?17/54/18286\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These mutations code for changes in either an arginine residue at position 201 or a glutamine residue at position 227 of the molecule. The mutant Gs-alpha molecules have decreased GTPase activity; as a result, the Gs-alpha-GTP complex is more stable, leading to constitutive activation of adenylyl cyclase.",
"   </p>",
"   <p>",
"    Among autonomously functioning thyroid adenomas, these mutations are less common than TSH-receptor mutations, occurring in 0 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/7,9,11\">",
"     7,9,11",
"    </a>",
"    ]. Gs-alpha mutations are also found in other endocrine tumors such as somatotroph adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/11\">",
"     11",
"    </a>",
"    ]. The occurrence of these mutations during embryogenesis also causes some of the manifestations of the McCune-Albright syndrome, including hyperthyroidism (with no goiter or a diffuse or multinodular goiter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link&amp;anchor=H3989453#H3989453\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'McCune-Albright syndrome'",
"    </a>",
"    .) Germline Gs-alpha mutations have not been reported, and are probably lethal.",
"   </p>",
"   <p>",
"    No autonomously functioning thyroid adenomas have been identified with mutations in both proteins, and some have no mutations in either. There are no clinical characteristics that distinguish among patients with TSH receptor mutations, Gs-alpha mutations, and no detectable mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER BENIGN THYROID NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common benign thyroid tumors are the nodules of multinodular goiters (colloid nodules) and follicular adenomas. The oncogene changes accounting for these benign thyroid nodules are not well delineated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multinodular goiters",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a tumor arises from a single cell, it is clonal. If it arises from all or most cells in a tissue, it is polyclonal. The nodules of multinodular goiters seemed polyclonal by morphologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/16\">",
"     16",
"    </a>",
"    ], but many are clonal by molecular studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The two types of studies, taken together, indicate that regions of phenotypic or functional heterogeneity can develop within a clonal thyroid nodule.",
"   </p>",
"   <p>",
"    Multinodular goiters are occasionally familial, which means that the patient has at least one germline mutation. One familial form of nontoxic multinodular goiter has been linked to DNA markers on chromosome 14q [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/19\">",
"     19",
"    </a>",
"    ], but the etiologic gene is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Follicular adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;As anticipated from pathologic studies, follicular adenomas are clonal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/20\">",
"     20",
"    </a>",
"    ]. Point mutations in the",
"    <em>",
"     HRAS",
"    </em>",
"    ,",
"    <em>",
"     KRAS",
"    </em>",
"    , and",
"    <em>",
"     NRAS",
"    </em>",
"    proto-oncogenes have been identified in both follicular adenomas and follicular cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-quarter of sporadic follicular adenomas have a hemizygous deletion of a chromosome region containing",
"    <em>",
"     PTEN",
"    </em>",
"    (MMAC1), the tumor suppressor gene in which germline defects cause Cowden's disease (multiple hamartomas and breast, thyroid, and other tumors). Because defects in both alleles of a tumor suppressor gene are needed for tumor formation, it remains unclear whether inactivation of",
"    <em>",
"     PTEN",
"    </em>",
"    itself or a different tumor suppressor gene on chromosome 10q is a cause of sporadic follicular thyroid adenomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 50 percent of follicular adenomas associated with external radiation are reported to have rearrangements of the",
"    <em>",
"     RET",
"    </em>",
"    proto-oncogene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/26\">",
"     26",
"    </a>",
"    ]. This is unexpected, because",
"    <em>",
"     RET",
"    </em>",
"    mutations are rare in sporadic follicular adenomas or cancers.",
"   </p>",
"   <p>",
"    Chromosomal translocations involving 19q13 and 2p21 are found in follicular adenomas, and do not co-occur in the same neoplasm. Based upon analysis of a small number of follicular adenomas, the 19q13 rearranged gene is",
"    <em>",
"     ZNF331",
"    </em>",
"    (HUGO nomenclature) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/27\">",
"     27",
"    </a>",
"    ], and the 2q21 rearranged gene is referred to as thyroid adenoma-associated gene (",
"    <em>",
"     THADA",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/28\">",
"     28",
"    </a>",
"    ]. THADA may be a death receptor-interacting protein. Both genes may be rearranged with different partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PAPILLARY THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary thyroid cancers frequently carry gene mutations and rearrangements that lead to activation of the mitogen activated protein kinase (MAPK) that promotes cell division. Rearrangements of RET and NTRK1 tyrosine kinases, activating mutations of BRAF, and activating mutations of RAS are sequential components leading to activation of MAPK (",
"    <a class=\"graphic graphic_figure graphicRef71801 \" href=\"mobipreview.htm?29/33/30237\">",
"     figure 2",
"    </a>",
"    ). Any given papillary thyroid cancer carries only a single one of these genetic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     RET and NTRK1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary thyroid cancers are associated with rearrangements of two different transmembrane tyrosine kinase genes:",
"    <em>",
"     RET",
"    </em>",
"    and",
"    <em>",
"     NTRK1",
"    </em>",
"    . These rearrangements result in the production of chimeric proteins with constitutive tyrosine kinase activity that contributes to the development of the malignant phenotype (",
"    <a class=\"graphic graphic_figure graphicRef70230 \" href=\"mobipreview.htm?20/50/21293\">",
"     figure 3",
"    </a>",
"    ). The chimeric genes resulting from",
"    <em>",
"     RET",
"    </em>",
"    rearrangements are referred to as",
"    <span class=\"nowrap\">",
"     <em>",
"      RET/PTC",
"     </em>",
"    </span>",
"    and those resulting from",
"    <em>",
"     NTRK1",
"    </em>",
"    rearrangements as",
"    <em>",
"     TRK",
"    </em>",
"    (",
"    <a class=\"graphic graphic_table graphicRef72255 \" href=\"mobipreview.htm?20/2/20523\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       RET",
"      </em>",
"      codes for a glial cell line-derived neurotrophic factor receptor with tyrosine kinase activity. Germline RET mutations cause the MEN-2 syndromes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41495?source=see_link\">",
"       \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       NTRK1",
"      </em>",
"      codes for a nerve growth factor receptor that also has tyrosine kinase activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither of these genes is expressed in normal thyroid epithelial cells. As a result, patients with MEN2 syndromes do not have an increased incidence of papillary thyroid cancer.",
"   </p>",
"   <p>",
"    In somatic rearrangements of the",
"    <em>",
"     RET",
"    </em>",
"    or",
"    <em>",
"     NTRK1",
"    </em>",
"    genes, the attachment of new genetic material to the 5' end of the tyrosine kinase domain of the gene leads to a constitutive increase in tyrosine kinase activity that activates growth pathways and may be sufficient to cause the papillary cancer phenotype (",
"    <a class=\"graphic graphic_figure graphicRef70230 \" href=\"mobipreview.htm?20/50/21293\">",
"     figure 3",
"    </a>",
"    ). This etiologic role has been confirmed in transgenic mice, in which an activated RET gene in thyroid epithelial cells causes papillary cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of gene rearrangements involving",
"    <em>",
"     RET",
"    </em>",
"    and",
"    <em>",
"     NTRK1",
"    </em>",
"    in papillary thyroid cancers has varied in different studies. In adults, approximately 40 percent of sporadic papillary cancers have these rearrangements, with those in",
"    <em>",
"     RET",
"    </em>",
"    being about three times more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/33\">",
"     33",
"    </a>",
"    ]. The incidence of",
"    <em>",
"     RET",
"    </em>",
"    rearrangements in papillary cancers is higher in children (about 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and is about 80 percent in the papillary cancers of children exposed to external x-irradiation and those exposed to radiation after the Chernobyl nuclear accident in 1986 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/26,34\">",
"     26,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are at least six chimeric",
"    <span class=\"nowrap\">",
"     <em>",
"      RET/PTC",
"     </em>",
"    </span>",
"    and",
"    <em>",
"     TRK",
"    </em>",
"    genes (",
"    <a class=\"graphic graphic_table graphicRef72255 \" href=\"mobipreview.htm?20/2/20523\">",
"     table 2",
"    </a>",
"    ). Their clinical importance seems to be similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/26,33,34,36-41\">",
"     26,33,34,36-41",
"    </a>",
"    ], but papillary cancers with",
"    <em>",
"     TRK",
"    </em>",
"    and",
"    <span class=\"nowrap\">",
"     <em>",
"      RET/PTC",
"     </em>",
"    </span>",
"    rearrangements may be more aggressive than papillary cancers without them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     BRAF mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BRAF isoform of RAF has been implicated in the pathogenesis of papillary thyroid cancer, but not of benign or follicular neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/29\">",
"     29",
"    </a>",
"    ]. The RAF proteins are serine-threonine kinases that activate the",
"    <span class=\"nowrap\">",
"     RAF/MEK/MAPK",
"    </span>",
"    signaling pathway. The T1799A mutation of the",
"    <em>",
"     BRAF",
"    </em>",
"    gene, which was originally found in over 50 percent of malignant melanomas and a smaller percentage of colon cancers, occurs in 29 to 69 percent of papillary thyroid cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/29,42-44\">",
"     29,42-44",
"    </a>",
"    ]. The predicted protein product BRAFV600E has increased basal kinase activity and transforms NIH3T3 cells with a higher efficiency than does the wild type BRAF, and transgenic mice expressing this mutation develop PTC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report,",
"    <em>",
"     BRAF",
"    </em>",
"    mutations were found in 219 of 500 patients with papillary thyroid cancer (44 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/46\">",
"     46",
"    </a>",
"    ]. BRAF V600E, the most prevalent mutation, was associated with invasive tumor growth and the follicular variant of papillary cancer.",
"   </p>",
"   <p>",
"    <em>",
"     BRAF",
"    </em>",
"    mutations may confer a worse clinical prognosis than for papillary thyroid cancer without the",
"    <em>",
"     BRAF",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/47\">",
"     47",
"    </a>",
"    ]. Recurrence occurs more frequently when",
"    <em>",
"     BRAF",
"    </em>",
"    mutations are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition,",
"    <em>",
"     BRAF",
"    </em>",
"    mutations are associated with extrathyroidal invasion, lymph node metastases and advanced tumor stage at initial surgery, although for these findings, conventional histologic evaluation was as effective in predicting outcome as was the presence of the",
"    <em>",
"     BRAF",
"    </em>",
"    mutation. Interestingly, some lymph node metastases may acquire additional",
"    <em>",
"     BRAF",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     BRAF",
"    </em>",
"    point mutations appear to be much less common in childhood thyroid cancers, including those that developed after the Chernobyl accident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, an oncogene (",
"    <em>",
"     AKAP9-BRAF",
"    </em>",
"    ) that derives from a paracentric inversion of the long arm of chromosome 7 has been identified in radiation-associated papillary thyroid cancers developing after a short latency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because",
"    <em>",
"     BRAF",
"    </em>",
"    mutations are not found in follicular carcinomas and benign thyroid nodules, identification of a",
"    <em>",
"     BRAF",
"    </em>",
"    mutation may aid in the diagnosis and management of papillary thyroid cancer. In a preliminary report,",
"    <em>",
"     BRAF",
"    </em>",
"    mutations were detected in blood samples from patients with papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/54\">",
"     54",
"    </a>",
"    ]. BRAF positivity correlated with the presence of residual or metastatic disease. In addition, the detection of",
"    <em>",
"     BRAF",
"    </em>",
"    gene mutations in fine needle aspiration biopsy specimens may prove useful in the assessment of follicular lesions. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link&amp;anchor=H15#H15\">",
"     \"Thyroid biopsy\", section on 'Follicular neoplasm (microfollicular)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In thyroid cancer cell lines harboring activated BRAF, the addition of selective inhibitors of BRAF inhibited proliferation of BRAF mutant cell lines, suggesting a possible role of such inhibitors in the treatment of patients with papillary thyroid cancer and",
"    <em>",
"     BRAF",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     RAS mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although activating ras mutations are found in follicular adenomas, they have also been reported in follicular variant of papillary thyroid cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <em>",
"     NRAS",
"    </em>",
"    mutations are more common than",
"    <em>",
"     HRAS",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Common sequence variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large population studies have identified multiple different single nucleotide polymorphisms (SNPs) that are associated with a clinically modest, but statistically significant, increased risk of well-differentiated thyroid carcinoma, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       G/C",
"      </span>",
"      heterozygosity within the precursor of microRNA-146a predisposes to PTC (OR 1.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/59\">",
"       59",
"      </a>",
"      ]. This polymorphism alters the microRNA sequence and induces microRNA overexpression with new microRNA forms that alter target gene expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SNPs at 9q22.33 that are close to",
"      <em>",
"       FOXE1",
"      </em>",
"      (",
"      <em>",
"       TTF2",
"      </em>",
"      ) and at 14q13.3 that are close to",
"      <em>",
"       NKX2-1",
"      </em>",
"      (",
"      <em>",
"       TTF1",
"      </em>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/61\">",
"       61",
"      </a>",
"      ]. Both FOXE1 and NKX2-1 are known to regulate gene transcription within the thyroid cells.",
"     </li>",
"     <li>",
"      SNPs found in CHEK2, NBS1, XRCC3, and the promoter of RAD51 have all been associated with an increased risk of differentiated thyroid cancer, which are mostly PTC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/62-65\">",
"       62-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other genetic abnormalities in PTC",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs (miRNAs) modify gene expression by binding to specific targets in the 3' untranslated region and are being implicated in tumorigenesis of a variety of tissues. Several miRNAs (miR-221, miR-222, miR-146, and others) are up-regulated in PTC and may contribute to tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methylation often decreases gene expression and may contribute to tumorigenesis. Increased methylation of several tumor suppressor genes (",
"    <em>",
"     TIMP3, SLC5A8, DAPK,",
"    </em>",
"    and",
"    <em>",
"     RARbeta2",
"    </em>",
"    ) is associated with features of PTC aggressiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small fraction of papillary cancers have deletions in the expressed RNA for",
"    <span class=\"nowrap\">",
"     p21/Waf1,",
"    </span>",
"    a cell cycle-inhibitor protein. The changes are present in the RNA, but not the gene, which suggests a splicing alteration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/69\">",
"     69",
"    </a>",
"    ]. Their importance in thyroid tumorigenesis remains to be established.",
"   </p>",
"   <p>",
"    There may be an increased incidence of papillary cancer in patients with familial adenomatous polyposis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/70\">",
"     70",
"    </a>",
"    ]. This disorder is caused by germline mutations of the APC gene, a tumor suppressor gene of unknown function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .) In comparison, somatic mutations of this gene are uncommon in sporadic papillary cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/71\">",
"     71",
"    </a>",
"    ]. The papillary thyroid cancers of patients with familial adenomatous polyposis may have rearrangements of RET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Papillary thyroid cancers are usually sporadic, but can occur as a familial syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. Powerful genetic linkage methodologies can be applied to these disorders to identify the susceptibility genes. A familial variant of papillary thyroid cancer has been linked to chromosome 19p13.2 and is associated with benign thyroid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/77\">",
"     77",
"    </a>",
"    ]. A familial predisposition to papillary thyroid cancer and papillary renal tumors has been linked to chromosome 1q21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other family studies have indicated a familial predisposition at 2q21 to PTC, as well as a familial predisposition at 8q24 to PTC with melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/79\">",
"     79",
"    </a>",
"    ]. There may be additional susceptibility genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome of thyroid tumor with cell oxyphilia (TCO) that has been linked to 19p13.2 is associated with mutations of a mitochondrial inner membrane translocase called TIMM44. Since these mutations did not have any obvious effect on protein function, their role in tumorigenesis remains to be elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased incidence of papillary thyroid cancer is found in patients with congenital hypothyroidism with huge goiters caused by thyroglobulin gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/82\">",
"     82",
"    </a>",
"    ]. Therefore, thyroglobulin gene mutations may confer a predisposition to the development of thyroid cancer, since they lead to excessive TSH stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FOLLICULAR THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chromosomal translocation has been identified in follicular cancers that may distinguish them from papillary cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/83\">",
"     83",
"    </a>",
"    ]. The translocation (t(2;3)[q13;p25]) results in fusion of part of the DNA-binding segment of the PAX8 gene and the peroxisome proliferator-activated receptor gamma 1 (PPAR-gamma-1) gene; PAX8 is a thyroid transcription factor and PPAR-gamma-1 is a transcription factor that stimulates cell differentiation and inhibits cell growth.",
"   </p>",
"   <p>",
"    The product of the fusion gene blocks the action of the PPAR-gamma-1, an effect that might inhibit cell differentiation and stimulate cell growth. In one study, the translocation was found in five of eight follicular cancers and 0 of 20 follicular adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/83\">",
"     83",
"    </a>",
"    ], and in another study it was found in five of nine cancers and 2 of 16 adenomas, suggesting that it may be useful for distinguishing between follicular cancers and follicular adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/84\">",
"     84",
"    </a>",
"    ]. However, further investigation, including the study of large numbers of tumors with careful clinical-pathological correlation, will be needed to determine the true clinical utility of this molecular finding.",
"   </p>",
"   <p>",
"    Overexpression of normal",
"    <em>",
"     c-myc",
"    </em>",
"    and",
"    <em>",
"     c-fos",
"    </em>",
"    genes, as well as mutations of",
"    <em>",
"     HRAS",
"    </em>",
"    ,",
"    <em>",
"     NRAS",
"    </em>",
"    , and",
"    <em>",
"     KRAS",
"    </em>",
"    proto-oncogenes, are found in follicular adenomas, follicular cancers, and occasionally papillary cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/21-23,25,85\">",
"     21-23,25,85",
"    </a>",
"    ]. These abnormalities may confer a growth-promoting effect that is not specific for tumor type, but may act additively with other oncogene or tumor suppressor gene mutations. Acquired subchromosomal deletions (allelic losses) in these genes occur more often in follicular cancers than in follicular adenomas or papillary cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/86\">",
"     86",
"    </a>",
"    ]. About 30 percent of follicular thyroid cancers have RAS mutations with the",
"    <em>",
"     NRAS",
"    </em>",
"    mutations being more common than",
"    <em>",
"     HRAS",
"    </em>",
"    and",
"    <em>",
"     KRAS",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Germline mutations in PTEN, a tumor suppressor gene, have been described in a variety of rare syndromes that are collectively known as the PTEN hamartoma tumor syndromes (PHTS). Cowden syndrome is the best described syndrome within PHTS. In addition to benign follicular adenomas, individuals with Cowden syndrome have an approximately 70-fold increased incidence of thyroid cancer relative to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/87\">",
"     87",
"    </a>",
"    ]. Both follicular and papillary neoplasms may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=see_link&amp;anchor=H462459934#H462459934\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Thyroid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypermethylation of RASSF1A, a known tumor suppressor gene, has been described in 75 percent of follicular thyroid cancers (9 of 12) as well as in a smaller percentage of benign adenomas (44 percent), and papillary thyroid cancers (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/88\">",
"     88",
"    </a>",
"    ]. This may be an early step in thyroid epithelial tumorigenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANAPLASTIC THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic thyroid cancers are the most aggressive of the thyroid cancers. Mutations of the p53 tumor suppressor gene that lead to production of an inactive p53 protein occur in most anaplastic thyroid cancers, and not in other thyroid cancers except for an occasional follicular cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/89\">",
"     89",
"    </a>",
"    ]. The protein product of the p53 gene is a transcription factor that regulates both apoptosis and the cell cycle. Nearly one-half of all human cancers have mutations in this gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations within exon 3 of the beta-catenin gene (",
"    <em>",
"     CTNNNB1",
"    </em>",
"    ) occur in up to 65 percent of anaplastic thyroid carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/91\">",
"     91",
"    </a>",
"    ]. The beta-catenin protein plays a role in cell adhesion and in signaling through the WNT pathway. The exon 3 mutations are associated with increased nuclear localization of the beta-catenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/91\">",
"     91",
"    </a>",
"    ]. Thus, these mutations may result in increased nuclear signaling and subsequent tumorigenesis or tumor progression.",
"   </p>",
"   <p>",
"    Based upon the suggestion that differentiated thyroid cancers may degenerate into anaplastic thyroid cancers, it has been proposed that several different gene mutations provide an early growth advantage and that p53 mutations are the final critical step in the development of an anaplastic cancer. However, in one study of 17 anaplastic cancers, no RET gene rearrangements were detected, providing no evidence for the evolution of papillary into anaplastic thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, another study found that 10 percent (3 of 31) of anaplastic thyroid cancers contained a T to A transversion at nucleotide 1796 of the",
"    <em>",
"     BRAF",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/93\">",
"     93",
"    </a>",
"    ]. These anaplastic thyroid cancers had well differentiated regions suggesting papillary thyroid cancer that also contained the same mutation. Therefore, it seems likely that in some cases papillary thyroid cancer may dedifferentiate into anaplastic thyroid cancer. This finding has been confirmed by others, suggesting that some PTC may transform to anaplastic thyroid cancer when a p53 mutation occurs following the initial",
"    <em>",
"     BRAF",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatic mutations of the catalytic subunit of the phosphatidylinositol 3'-kinase (PIK3CA) have been identified in about 23 percent of anaplastic thyroid cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/95\">",
"     95",
"    </a>",
"    ]. In anaplastic thyroid cancers with well differentiated components, the PIK3CA mutations are restricted to the anaplastic component, suggesting that these are late events in tumorigenesis that contribute to the transition from a well differentiated to anaplastic phenotype. The PIK3CA is an intermediary molecule linking RAS activation and loss of PTEN inhibition to AKT (also known as protein kinase B) activation. Mutations of PIK3CA have been reported in about 25 to 40 percent of colorectal, gastric, breast, and ovarian cancers.",
"   </p>",
"   <p>",
"    Somatic mutations within the tyrosine kinase domain of the anaplastic lymphoma kinase (",
"    <em>",
"     ALK",
"    </em>",
"    ) gene were found in 2 of 18 anaplastic thyroid cancers. Of the 36 PTC examined, none carried mutations of this gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/96\">",
"     96",
"    </a>",
"    ]. ALK is a tyrosine kinase that shares structural similarity with the insulin receptor. Fusion proteins involving the ALK tyrosine kinase domain and activating ALK mutations are tumorigenic in other tissues.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H308502\">",
"    <span class=\"h1\">",
"     MicroRNA EXPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some microRNAs (miRNA) are differentially expressed in malignant and benign thyroid tissue. Although the tumorigenic significance of these changes is not known, the expression differences may be useful in distinguishing benign from malignant neoplasms, predicting outcome, or directing therapy. Expression profiling has identified several miRNAs that are differentially expressed in benign and malignant thyroid neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/97\">",
"     97",
"    </a>",
"    ]. The molecular profiling of thyroid neoplasms is commercially available to help distinguish benign from malignant thyroid nodules using RNA from cells obtained by fine needle aspiration biopsy. It is anticipated that the accuracy of this molecular testing will improve rapidly over the next several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H308509\">",
"    <span class=\"h1\">",
"     MITOCHONDRION-RICH TUMORS AND MUTATIONS OF MITOCHONDRIAL COMPLEX 1 GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some benign and malignant thyroid tumors are found to have an increased number of mitochondria and are referred to as oxyphil or H&uuml;rthle cell tumors. Mitochondrial complex 1 is the first enzyme in the mitochondrial respiratory chain and releases hydrogen ions from NADH. The hydrogen ion gradient is used to power ATP formation. The proteins of complex 1 are derived from both mitochondrial and nuclear genes. Disruptive somatic mutations of mitochondrial genes and of the nuclear gene",
"    <em>",
"     GRIM-19",
"    </em>",
"    that code for complex 1 proteins are significantly associated with the oncocytic phenotype in both benign and malignant thyroid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/20/43337/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. It is not known if these mutations develop in response to the tumorigenic changes or if they themselves are tumorigenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our knowledge of the molecular pathogenesis of benign and malignant thyroid neoplasia is evolving. The molecular profiling of thyroid neoplasms is commercially available to help distinguish benign from malignant thyroid nodules using RNA from cells obtained by fine needle aspiration biopsy. It is anticipated that the accuracy of this molecular testing will improve rapidly over the next several years. Molecular profiling is not yet clinically indicated to direct therapy of established thyroid cancers. However, investigations into the molecular pathogenesis of thyroid neoplasms are being pursued aggressively and are likely to have clinically useful therapeutic implications in the future.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autonomously functioning thyroid nodules are benign tumors that produce thyroid hormone. Many of these tumors are caused by somatic mutations in genes that code for the TSH receptor or the alpha subunit of the guanyl nucleotide stimulatory protein (Gs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Autonomously functioning thyroid adenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common benign thyroid tumors are the nodules of multinodular goiters (colloid nodules) and follicular adenomas. The oncogene changes accounting for these benign thyroid nodules are not well delineated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Other benign thyroid nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Papillary thyroid cancers frequently carry gene mutations and rearrangements that lead to activation of the mitogen activated protein kinase (MAPK) that promotes cell division. Rearrangements of RET and NTRK1 tyrosine kinases, activating mutations of BRAF and activating mutations of RAS are sequential components leading to activation of MAPK (",
"      <a class=\"graphic graphic_figure graphicRef71801 \" href=\"mobipreview.htm?29/33/30237\">",
"       figure 2",
"      </a>",
"      ). Any given papillary thyroid cancer carries only a single one of these genetic changes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Papillary thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overexpression of normal c-myc and c-fos genes, as well as mutations of",
"      <em>",
"       HRAS",
"      </em>",
"      ,",
"      <em>",
"       NRAS",
"      </em>",
"      , and",
"      <em>",
"       KRAS",
"      </em>",
"      proto-oncogenes, is found in follicular adenomas, follicular cancers, and occasionally papillary cancers. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Follicular thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaplastic thyroid cancers are the most aggressive of the thyroid cancers. Mutations of the p53 tumor suppressor gene that lead to production of an inactive p53 protein occur in most anaplastic thyroid cancers and not in other thyroid cancers except for an occasional follicular cancer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anaplastic thyroid cancer'",
"      </a>",
"      above.) Anaplastic thyroid carcinomas may also harbor mutations of",
"      <em>",
"       BRAF",
"      </em>",
"      ,",
"      <em>",
"       ALK",
"      </em>",
"      , and",
"      <em>",
"       PIK3CA",
"      </em>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/1\">",
"      Porcellini A, Ruggiano G, Pannain S, et al. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells. Oncogene 1997; 15:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/2\">",
"      Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/3\">",
"      Paschke R, Tonacchera M, Van Sande J, et al. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab 1994; 79:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/4\">",
"      Porcellini A, Ciullo I, Laviola L, et al. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 1994; 79:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/5\">",
"      Russo D, Arturi F, Wicker R, et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995; 80:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/6\">",
"      Russo D, Arturi F, Suarez HG, et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996; 81:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/7\">",
"      F&uuml;hrer D, Holzapfel HP, Wonerow P, et al. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/8\">",
"      Kopp P, van Sande J, Parma J, et al. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995; 332:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/9\">",
"      O'Sullivan C, Barton CM, Staddon SL, et al. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991; 4:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/10\">",
"      Suarez HG, du Villard JA, Caillou B, et al. gsp mutations in human thyroid tumours. Oncogene 1991; 6:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/11\">",
"      Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/12\">",
"      Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A 1992; 89:5152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/13\">",
"      Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/14\">",
"      Malchoff CD, Reardon G, MacGillivray DC, et al. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 1994; 78:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/15\">",
"      Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/16\">",
"      Ramelli F, Studer H, Bruggisser D. Pathogenesis of thyroid nodules in multinodular goiter. Am J Pathol 1982; 109:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/17\">",
"      Apel RL, Ezzat S, Bapat BV, et al. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 1995; 4:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/18\">",
"      Aeschimann S, Kopp PA, Kimura ET, et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 1993; 77:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/19\">",
"      Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997; 61:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/20\">",
"      Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest 1990; 86:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/21\">",
"      Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/22\">",
"      Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/23\">",
"      Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/24\">",
"      Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/25\">",
"      Karga H, Lee JK, Vickery AL Jr, et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991; 73:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/26\">",
"      Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997; 15:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/27\">",
"      Belge G, Rippe V, Meiboom M, et al. Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations. Cytogenet Cell Genet 2001; 93:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/28\">",
"      Rippe V, Drieschner N, Meiboom M, et al. Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 2003; 22:6111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/29\">",
"      Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/30\">",
"      Indo Y, Mardy S, Tsuruta M, et al. Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor. Jpn J Hum Genet 1997; 42:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/31\">",
"      Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996; 137:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/32\">",
"      Santoro M, Chiappetta G, Cerrato A, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996; 12:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/33\">",
"      Bongarzone I, Vigneri P, Mariani L, et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 1998; 4:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/34\">",
"      Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/35\">",
"      Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/36\">",
"      Bongarzone I, Butti MG, Fugazzola L, et al. Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics 1997; 42:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/37\">",
"      Greco A, Miranda C, Pagliardini S, et al. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer 1997; 19:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/38\">",
"      Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/39\">",
"      Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident. Oncogene 1996; 13:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/40\">",
"      Fugazzola L, Pierotti MA, Vigano E, et al. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 1996; 13:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/41\">",
"      Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res 1997; 47:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/42\">",
"      Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/43\">",
"      Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004; 10:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/44\">",
"      Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/45\">",
"      Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65:4238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/46\">",
"      Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92:4085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/47\">",
"      Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011; 17:7511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/48\">",
"      Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/49\">",
"      Vasko V, Hu S, Wu G, et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 2005; 90:5265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/50\">",
"      Oler G, Ebina KN, Michaluart P Jr, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 2005; 62:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/51\">",
"      Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:4267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/52\">",
"      Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:4280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/53\">",
"      Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005; 115:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/54\">",
"      Cradic KW, Milosevic D, Rosenberg AM, et al. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 2009; 94:5001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/55\">",
"      Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010; 95:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/56\">",
"      Ball DW. Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab 2010; 95:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/57\">",
"      Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/58\">",
"      Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/59\">",
"      Jazdzewski K, Murray EL, Franssila K, et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008; 105:7269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/60\">",
"      Jazdzewski K, Liyanarachchi S, Swierniak M, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009; 106:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/61\">",
"      Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 2009; 41:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/62\">",
"      Sturgis EM, Zhao C, Zheng R, Wei Q. Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope 2005; 115:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/63\">",
"      Cybulski C, G&oacute;rski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/64\">",
"      Adjadj E, Schlumberger M, de Vathaire F. Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol 2009; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/65\">",
"      Bastos HN, Ant&atilde;o MR, Silva SN, et al. Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid 2009; 19:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/66\">",
"      He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102:19075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/67\">",
"      Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 119:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/68\">",
"      Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007; 148:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/69\">",
"      Shi Y, Zou M, Farid NR, al-Sedairy ST. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer 1996; 74:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/70\">",
"      Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/71\">",
"      Zeki K, Spambalg D, Sharifi N, et al. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 1994; 79:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/72\">",
"      Cetta F, Chiappetta G, Melillo RM, et al. The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J Clin Endocrinol Metab 1998; 83:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/73\">",
"      Houlston RS, Stratton MR. Genetics of non-medullary thyroid cancer. QJM 1995; 88:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/74\">",
"      Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997; 7:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/75\">",
"      Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol 1999; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/76\">",
"      Malchoff CD, Malchoff DM. The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/77\">",
"      Canzian F, Amati P, Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998; 63:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/78\">",
"      Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000; 85:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/79\">",
"      McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001; 69:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/80\">",
"      Lesueur F, Stark M, Tocco T, et al. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab 1999; 84:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/81\">",
"      Bonora E, Evangelisti C, Bonichon F, et al. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer 2006; 95:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/82\">",
"      Hishinuma A, Fukata S, Kakudo K, et al. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid 2005; 15:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/83\">",
"      Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/84\">",
"      Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002; 87:3947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/85\">",
"      Terrier P, Sheng ZM, Schlumberger M, et al. Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. Br J Cancer 1988; 57:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/86\">",
"      Ward LS, Brenta G, Medvedovic M, Fagin JA. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 1998; 83:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/87\">",
"      Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011; 96:E2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/88\">",
"      Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004; 64:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/89\">",
"      Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/90\">",
"      Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/91\">",
"      Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/92\">",
"      Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/93\">",
"      Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/94\">",
"      Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/95\">",
"      Garc&iacute;a-Rost&aacute;n G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005; 65:10199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/96\">",
"      Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011; 71:4403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/97\">",
"      Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/98\">",
"      M&aacute;ximo V, Botelho T, Capela J, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005; 92:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/20/43337/abstract/99\">",
"      Gasparre G, Porcelli AM, Bonora E, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 2007; 104:9001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7819 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43337=[""].join("\n");
var outline_f42_20_43337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTONOMOUSLY FUNCTIONING THYROID ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Activating mutations of the TSH receptor gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gs-alpha gene mutations that activate adenylyl cyclase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER BENIGN THYROID NODULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multinodular goiters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Follicular adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PAPILLARY THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RET and NTRK1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BRAF mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RAS mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Common sequence variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other genetic abnormalities in PTC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FOLLICULAR THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANAPLASTIC THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H308502\">",
"      MicroRNA EXPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H308509\">",
"      MITOCHONDRION-RICH TUMORS AND MUTATIONS OF MITOCHONDRIAL COMPLEX 1 GENES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7819|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/54/18286\" title=\"figure 1\">",
"      Mutations in TSH cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/33/30237\" title=\"figure 2\">",
"      MAP kinase signal cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/50/21293\" title=\"figure 3\">",
"      Chimeric TK in pap thyroid Ca",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/54/8044\" title=\"table 1\">",
"      Oncogenes thyroid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/2/20523\" title=\"table 2\">",
"      Tyrosine kinase chimeras",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19988?source=related_link\">",
"      Chapter 6A: Mechanisms of hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21688?source=related_link\">",
"      Overview of follicular thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8440?source=related_link\">",
"      Overview of papillary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_20_43338="Mild FGS Light";
var content_f42_20_43338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67677%7ENEPH%2F63456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67677%7ENEPH%2F63456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows early changes in focal glomerulosclerosis with segmental capillary collapse (arrows) in areas of epithelial cell injury (small arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in focal segmental glomerulosclerosis shows a moderately large segmental area of sclerosis with capillary collapse on the upper left side of the glomerular tuft; the lower right segment is relatively normal. Focal deposition of hyaline material (arrow) is also seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43338=[""].join("\n");
var outline_f42_20_43338=null;
var title_f42_20_43339="Dust mites avoidance measures";
var content_f42_20_43339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Avoidance measures for dust mites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       First: Bedrooms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cover pillows and mattresses with zippered covers which are impermeable to mites and mite allergens.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wash sheets, pillowcases, and blankets in warm water with detergent or dry in an electric dryer on the hot setting weekly; when necessary, blankets should be replaced with those that can be washed. Comforters should be removed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use washable, vinyl, or roll-type window covers.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Remove clutter, soft toys, and upholstered furniture.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Where possible, carpets should be removed or replaced with area rugs that can be cleaned/washed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Second: Rest of house",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce upholstered furniture, particularly old sofas.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Replace carpets with polished flooring where possible. Carpets on concrete slabs or over poorly ventilated crawl spaces are a problem and should be replaced with polished flooring if possible.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vacuum weekly using a cleaner with a HEPA filtration system.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Window coverings should be washable, vinyl, or roll type.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Control humidity to &lt;50 percent relative humidity at normal temperatures, ie, 68 to 72&deg;F.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Third: Changing houses*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In general, allergy sufferers should not be encouraged to move from their home except in those cases where they are living in basements or overtly damp housing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Individuals who are allergic to mites (or molds) should be advised about the potential benefit of moving to an apartment (2nd floor or higher) or a house with 2nd floor bedrooms and wooden floors.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The average family in the United States moves approximately every four years.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43339=[""].join("\n");
var outline_f42_20_43339=null;
var title_f42_20_43340="Patient need at discharge";
var content_f42_20_43340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Model to categorize patient needs at discharge",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       <p>",
"        Patient profiles are divided into four broad domains:",
"       </p>",
"       <p>",
"        <strong>",
"         Domain I: Medical/surgical issues",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Domain II: Mental status/emotions/coping",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Domain III: Physical functioning",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Domain IV: Living environment - physical, social, financial",
"        </strong>",
"       </p>",
"       <p>",
"        Patient-specific elements within each domain, characterized by intensity (high-medium-low) are then determined, to create a profile that can be matched to the capabilities of alternative sites of care.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Domain I. Medical/surgical issues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Clinical instability. The probability that the patient will need rapid intervention for an",
"       <strong>",
"        U",
"       </strong>",
"       nstable",
"       <strong>",
"        C",
"       </strong>",
"       linical",
"       <strong>",
"        C",
"       </strong>",
"       ondition (",
"       <strong>",
"        UCC",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Complexity of care. The probability that the patient will need a",
"       <strong>",
"        C",
"       </strong>",
"       omplex diagnostic or therapeutic",
"       <strong>",
"        P",
"       </strong>",
"       rocedure (",
"       <strong>",
"        CP",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. The intensity of",
"       <strong>",
"        N",
"       </strong>",
"       ursing services (",
"       <strong>",
"        RN",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. The intensity of",
"       <strong>",
"        P",
"       </strong>",
"       hysician services (",
"       <strong>",
"        MD",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Domain II. Mental status/emotions/coping",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. The extent of",
"       <strong>",
"        C",
"       </strong>",
"       ognitive",
"       <strong>",
"        I",
"       </strong>",
"       mpairment or",
"       <strong>",
"        D",
"       </strong>",
"       epression (",
"       <strong>",
"        CID",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Domain III. Physical functioning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. The presence of a",
"       <strong>",
"        W",
"       </strong>",
"       indow of",
"       <strong>",
"        O",
"       </strong>",
"       pportunity for",
"       <strong>",
"        R",
"       </strong>",
"       ehabilitation during which rehabilitation services are most effective and outcomes are optimal at a time when the patient has the physical capacity to participate (",
"       <strong>",
"        WOR",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Domain IV. Living environment - physical, social, financial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Limitations on care options due to",
"       <strong>",
"        M",
"       </strong>",
"       edical",
"       <strong>",
"        I",
"       </strong>",
"       nsurance",
"       <strong>",
"        C",
"       </strong>",
"       overage (",
"       <strong>",
"        MIC",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Limitations on life sustaining treatments/",
"       <strong>",
"        A",
"       </strong>",
"       dvanced",
"       <strong>",
"        D",
"       </strong>",
"       irective (",
"       <strong>",
"        AD",
"       </strong>",
"       ).",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: Siebens, H. Applying the Domain Management Model in Treating Patients with Chronic Disease. Jt Comm J Qual Improv 2001; 27:302.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43340=[""].join("\n");
var outline_f42_20_43340=null;
var title_f42_20_43341="Contents: Pediatric surgical emergencies";
var content_f42_20_43341=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric surgical emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric surgical emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Appendicitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32826\">",
"           Acute appendicitis in children: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/61/19416\">",
"           Acute appendicitis in children: Diagnostic imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/2/31785\">",
"           Acute appendicitis in children: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear nose and throat problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/58/26536\">",
"           Management of epistaxis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/23/24953\">",
"           Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33654\">",
"           Balanoposthitis in children: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/39/29302\">",
"           Paraphimosis: Definition, pathophysiology, and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hernia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intestinal malrotation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/48/20232\">",
"           Intestinal malrotation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intusussception",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35145\">",
"           Intussusception in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pyloric stenosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/29/3545\">",
"           Infantile hypertrophic pyloric stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rectal prolapse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/48/32519\">",
"           Overview of rectal prolapse in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1113E92AFB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f42_20_43341=[""].join("\n");
var outline_f42_20_43341=null;
var title_f42_20_43342="Treatment of deep neck space infections";
var content_f42_20_43342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual causative organisms and initial empiric antimicrobial regimens for suppurative peripharyngeal infections in adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual causative organisms",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Antimicrobial regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Normal host",
"       </td>",
"       <td class=\"subtitle2\">",
"        Compromised host",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Coverage for methicillin-resistant Staphylococcus aureus (MRSA) should be included for those with risk factors",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Peritonsillar abscess (Quinsy)",
"       </td>",
"       <td rowspan=\"3\">",
"        Group A streptococcus (S. pyogenes), Fusobacterium spp, Peptostreptococcus spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Ampicillin-sulbactam 3 g IV Q 6 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Cefepime 2 g IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR monotherapy with:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Penicillin G 2-4 MU IV Q 4-6 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Clindamycin 600 mg IV Q 6-8 h",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Suppurative parotitis",
"       </td>",
"       <td rowspan=\"3\">",
"        Staphylococcus aureus, viridans and other streptococci, Bacteroides spp, Peptostreptococcus spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Nafcillin 1.5 g IV Q 4 h",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Linezolid 600 mg orally or IV Q 12 h",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h or linezolid 600 mg orally or IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         one of the following regimens:",
"        </p>",
"        <ul>",
"         <li>",
"          Cefepime 2 g IV Q 12 h",
"          <strong>",
"           PLUS",
"          </strong>",
"          metronidazole 500 mg IV Q 6-8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Either metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Clindamycin 600 mg IV Q 6-8 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Submandibular space infections (Ludwig's angina)",
"       </td>",
"       <td rowspan=\"3\">",
"        Viridans and other streptococci, Staphylococcus spp, Peptostreptococcus spp, Bacteroides spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Ampicillin-sulbactam 3 g IV Q 6 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Cefepime 2 g IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR monotherapy with:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Penicillin G 2-4 MU IV Q 4-6 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Clindamycin 600 mg IV Q 6-8 h",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        Parapharyngeal or retropharyngeal space infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"3\">",
"        Odontogenic",
"       </td>",
"       <td rowspan=\"3\">",
"        Viridans and other streptococci, Staphylococcus spp, Peptostreptococcus spp, Bacteroides spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Ampicillin-sulbactam 3 g IV Q 6 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Cefepime 2 g IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR monotherapy with:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Penicillin G 2-4 MU IV Q 4-6 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Clindamycin 600 mg IV Q 6-8 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"3\">",
"        Rhinogenic",
"       </td>",
"       <td rowspan=\"3\">",
"        Streptococcus pneumoniae, Haemophilus influenzae, viridans and other streptococci, Bacteroides spp, Peptostreptococcus spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Ampicillin-sulbactam 3 g IV Q 6 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        Same as for odontogenic space infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Ceftriaxone 1 g IV Q 24 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Ciprofloxacin 400 mg Q 12 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Clindamycin 600 mg IV Q 6-8 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Otogenic",
"       </td>",
"       <td>",
"        Same as for rhinogenic space infections",
"       </td>",
"       <td>",
"        Same as for rhinogenic space infections",
"       </td>",
"       <td>",
"        Same as for odontogenic space infections",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Septic jugular thrombophlebitis (Lemierre syndrome)",
"       </td>",
"       <td rowspan=\"3\">",
"        Fusobacterium necrophorum; same as for peritonsillar abscess or odontogenic space infections",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Ampicillin-sulbactam 3 g IV Q 6 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        Same as for odontogenic space infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Penicillin G 2-4 MU IV Q 4-6 h",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Clindamycin 600 mg IV Q 6-8 h",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Prevertebral space infection",
"       </td>",
"       <td rowspan=\"3\">",
"        Staphylococcus aureus",
"        <sup>",
"         &loz;",
"        </sup>",
"        , facultative gram-negative bacilli",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Nafcillin 1.5 g IV Q 4 h",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Linezolid 600 mg orally or IV Q 12 h",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h or linezolid 600 mg orally or IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         one of the following regimens:",
"        </p>",
"        <strong>",
"         Combination therapy with:",
"        </strong>",
"        <ul>",
"         <li>",
"          Cefepime 2 g IV Q 12 h",
"          <strong>",
"           PLUS",
"          </strong>",
"          metronidazole 500 mg IV Q 6-8 h",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <strong>",
"         OR monotherapy with:",
"        </strong>",
"        <ul>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         gentamicin or tobramycin 1.7 mg/kg IV Q 8 h",
"         <strong>",
"          or",
"         </strong>",
"         5 mg/kg IV Q 24 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ciprofloxacin 400 mg IV Q 12 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ticarcillin-clavulanate 3.1 g IV Q 4 h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The doses recommended in this table are intended for patients with normal renal and hepatic function.",
"     <br>",
"      &Delta; Compromised hosts are at increased risk for facultative gram-negative bacilli, including extended-spectrum-&beta;-lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Vancomycin 15-20 mg/kg IV Q 12 h or linezolid 600 mg orally or IV Q 12 h should be added, or substituted for nafcillin, in patients with risk factors for MRSA infection. Risk factors for MRSA infection include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43342=[""].join("\n");
var outline_f42_20_43342=null;
var title_f42_20_43343="Limbic keratoconjunctivitis";
var content_f42_20_43343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior limbic keratoconjunctivitis in contact lens wearer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_20_43343=[""].join("\n");
var outline_f42_20_43343=null;
